Arcturus Therapeutics Holdings Inc. (ARCT) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Arcturus Therapeutics Holdings Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$26.8 M, a 153% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$107 M, a 196% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.7 M, a 418% decline from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $9.35 M.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$204 M, a 182% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$107 M -$26.8 M -$77.6 M -153% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$29.7 M -$11.7 M -$129 M -110% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $99.3 M -$16.2 M +$19 M +54% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $80.3 M -$52.6 M -$31 M -144% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-14
Q1 2023 $111 M $50.8 M +$102 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $9.35 M $117 M +$156 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$147 M -$35.3 M +$18.8 M +34.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$165 M -$21.6 M +$33 M +60.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$198 M -$51.2 M +$5.18 M +9.19% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$204 M -$38.7 M -$7.56 M -24.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$196 M -$54.1 M -$33.1 M -157% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$163 M -$54.6 M -$44.3 M -432% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$119 M -$56.3 M -$46.6 M -476% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$72.1 M -$31.1 M -$20.1 M -183% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$52 M -$21 M -$13.6 M -183% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$38.5 M -$10.3 M -$9.58 M -1398% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$28.9 M -$9.78 M -$2.89 M -42% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$26 M -$11 M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$7.43 M -$3.18 M -74.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$685 K +$9.27 M +93.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$6.88 M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q3 2018 -$4.25 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$9.95 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.